MedTrace Logo

Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal Impairment

NCT04646889 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2022-08-05

No results posted yet for this study

Summary

This is a 2-segment, multi-center, phase 1, open-label, study evaluating the pharmacokinetics and pharmacodynamics of AR882 in subjects with various degrees of renal impairment.

Conditions

  • Renal Impairment

Interventions

DRUG

AR882 Single Dose

A single dose of AR882

DRUG

AR882 Multiple Dose

AR882 taken once daily for 14 days

Sponsors & Collaborators

  • Iqvia Pty Ltd

    collaborator INDUSTRY

  • Arthrosi Therapeutics

    lead INDUSTRY

Principal Investigators

  • Vijay Hingorani, MD, PhD, MBA · Arthrosi Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-14
Primary Completion
2022-06-27
Completion
2022-06-27
FDA Drug
Yes

Countries

  • United States
  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04646889 on ClinicalTrials.gov